ArticleCancer cell2019
Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?
Article in Cancer cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Pooled it
- Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.Nature communications · 2022Trial
- From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma.Journal of personalized medicine · 2026Review
- Harnessing the abscopal effect: mechanistic insights and therapeutic strategies for systemic cancer immunotherapy.Frontiers in immunology · 2026Review
- Druggable genome CRISPR screening identifies the KEAP1/NRF2 axis as a mediator of PD-L1 expression.Communications biology · 2025Article
- Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives.Molecular cancer · 2025Review
- Fibroblast activation protein-α is a potential prognostic biomarker related to ferroptosis in head and neck squamous cell carcinoma.Biochemistry and biophysics reports · 2025Article
- Regulatory mechanisms of PD-1/PD-L1 in cancers.Molecular cancer · 2024Review
- Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.Medicina (Kaunas, Lithuania) · 2024Review
- Tumor histoculture captures the dynamic interactions between tumor and immune components in response to anti-PD1 in head and neck cancer.Nature communications · 2024Article
- T antigen-specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma.The Journal of clinical investigation · 2024Article
- Biology-driven therapy advances in high-grade serous ovarian cancer.The Journal of clinical investigation · 2024Review
- Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors.Journal of veterinary science · 2024Article
- Modulation of CD8International journal of molecular sciences · 2023Review
- PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion.Haematologica · 2023Article
- Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer.Nature cancer · 2022Article
- Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test.Diagnostic pathology · 2022Article
- PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.Frontiers in immunology · 2022Review
- Poor prognosis, hypomethylation, and immune infiltrates are associated with downregulation of INMT in head and neck squamous cell carcinoma.Frontiers in genetics · 2022Article
- Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy.European journal of immunology · 2021Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
It has been widely assumed that PD-1 blockade works by reinvigorating ("rebooting") pre-existing exhausted tumor-infiltrating ilymphocytes (TILs). A recent study challenges this paradigm, demonstrating that the majority of tumor-specific TILs after anti-PD-1 treatment have TCRs not identified in the tumor pre-therapy, suggesting they are newly recruited post-therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.